---
layout: post
title: "Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; RHAPSIDO (Remibrutinib)"
date: 2026-02-04 21:34:56 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2026-01084
original_published: 2026-01-21 00:00:00 +0000
significance: 8.00
---

# Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; RHAPSIDO (Remibrutinib)

**Published:** February 04, 2026 21:34 UTC
**Source:** Federal Register
**Original Published:** January 21, 2026 00:00 UTC
**Document Number:** 2026-01084

## Summary

The Food and Drug Administration (FDA) is announcing the issuance of approval of a product redeeming a priority review voucher. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the issuance of priority review vouchers as well as the approval of products redeeming a priority review voucher. FDA has determined that RHAPSIDO (remibrutinib), approved September 30, 2025, meets the criteria for redeeming a priority review voucher.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2026/01/21/2026-01084/notice-of-approval-of-product-under-voucher-rare-pediatric-disease-priority-review-voucher-rhapsido)
- API: https://www.federalregister.gov/api/v1/documents/2026-01084

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
